Back to top
more

Catalent (CTLT)

(Real Time Quote from BATS)

$60.04 USD

60.04
356,865

+0.09 (0.15%)

Updated Nov 7, 2024 11:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

LabCorp (LH) Q2 Earnings Surpass Estimates, 2021 View Raised

by Zacks Equity Research

LabCorp (LH) Diagnostics revenues in the second quarter increase significantly on organic Base Business volume improvements despite decelerating demand for COVID-19 testing.

CONMED's (CNMD) Q2 Earnings Surpass Estimates, '21 View Up

by Zacks Equity Research

CONMED (CNMD) witnesses revenue uptick in both of its segments during Q2 despite continued pandemic-led business disruptions.

Baxter (BAX) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Baxter's (BAX) second-quarter results reflect robust performance across all its business units.

West Pharmaceutical (WST) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter earnings reflect strong segmental performance.

Hologic's (HOLX) Q3 Earnings Top Estimates, Q4 View Dull

by Zacks Equity Research

Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.

Align Technology (ALGN) Q2 Earnings Top Estimates, 2021 View Up

by Zacks Equity Research

Strength in Invisalign Clear Aligners and iTero scanners sales volumes during the fiscal second quarter drove Align Technology's (ALGN) top line.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2021 View

by Zacks Equity Research

Thermo Fisher's (TMO) base business witnesses accelerated growth in the second quarter.

Masimo's (MASI) Q2 Earnings Surpass Estimates, '21 View Up

by Zacks Equity Research

Masimo's (MASI) robust product shipments, along with strong rebound in sensor sales, drive its Q2 sales.

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) second-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.

Chemed (CHE) Q2 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings and revenues with strong Roto-Rooter segment performance driving the top line in second-quarter 2021.

Ecolab (ECL) Q2 Earnings & Revenues Beat Mark, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performances across majority of its segments drive its Q2 sales despite pandemic-led business challenges.

Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up

by Zacks Equity Research

Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results benefit from strong segmental performance.

Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning

by Zacks Equity Research

Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.

Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.

Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong

by Zacks Equity Research

According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.

Abbott (ABT) Q2 Earnings Beat, Molecular Diagnostic Sales Drop

by Zacks Equity Research

Abbott's (ABT) Adult Nutrition sales benefit from improved sales performance of complete and balanced nutrition brand Ensure and diabetes nutrition brand, Glucerna in Q2.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) second-quarter results are likely to reflect continued strength in the Global Healthcare and Life Sciences segment.

Sanghamitra Saha headshot

Bet on Rising P/E Investing With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Neogen (NEOG) Misses Q4 Earnings, Tops Revenue Estimates

by Zacks Equity Research

Strong segmental revenues and solid international performance across Neogen's (NEOG) entire business drove its topline.

Intuitive Surgical (ISRG) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results reflect strong segmental performance.

FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote

by Zacks Equity Research

FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.

Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline

by Zacks Equity Research

Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.

Catalyst (CPRX) Thrives on Firdapse But Overdependence Concerns

by Zacks Equity Research

Catalyst's (CPRX) Firdapse is approved for treating Lambert-Eaton myasthenic syndrome. The drug has seen solid uptake since its launch. Sole dependence on Firdapse for growth remains a concern.

Catalent (CTLT) Inks Deal for Feasibility Study of CBD Product

by Zacks Equity Research

Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.